Expression of Angiogenesis Regulatory Proteins and Epithelial-Mesenchymal Transition Factors in Platelets of the Breast Cancer Patients
Table 1
Biomarker levels in PP and clinical characteristics.
Groups
Number of patients
PF4 (ng)
TGF- (ng)
VEGF (pg)
PDGF-BB (pg)
Stage
I+II
24
21.6 ± 11.3
16.5 ± 10.6a
2.37 ± 1.0a
40.4 ± 13.3a
III+IV
13
24.4 ± 11.5
24.6 ± 12.2
3.38 ± 1.28
49.9 ± 13.8
Age
>60
8
22.9 ± 11.8
23.1 ± 12.5
2.84 ± 1.12
50.3 ± 14.6
40–60
23
22.3 ± 11.6
20.16 ± 17.4
3.05 ± 1.23
46.3 ± 13.5
<40
6
23.3 ± 12.9
20.8 ± 18.0
2.89 ± 1.11
44.6 ± 13.1
LN status
N0
11
22.1 ± 11.2
16.4 ± 10.1b
2.32 ± 1.05b
40.2 ± 13.1b
N13
26
22.8 ± 12.1
24.5 ± 11.3
3.31 ± 1.14
49.8 ± 13.5
Molecular subtypes
Luminal A
9
21.9 ± 11.7
18.4 ± 11.6c
2.66 ± 1.09c
42.8 ± 13.4c
Luminal B
12
22.1 ± 12.3
19.7 ± 12.9
2.73 ± 1.17
43.2 ± 13.3
HER-2(+)
7
24.9 ± 12.9
28.9 ± 13.7
3.51 ± 1.25
52.1 ± 14.3
Basal like
9
22.2 ± 11.1
33.2 ± 15.2
3.74 ± 1.26
56.2 ± 14.7
Variables are normalized to actin and expressed per 106 platelets. Being constrained by relatively low number of candidates in each clinical subgroup, we used average content instead of median level to make the comparisons. aStages I+II versus III+IV: , bLN status N0 versus N1-3: , and cLuminal A or B versus HER-2 or Basal like: .